The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.

被引：12

作者：

Wang-Gillam, Andrea

Chen, Li-Tzong

Li, Chung-Pin

Bodoky, Gyorgy

Dean, Andrew

Lee, Kyung-Hun

Cunningham, David

Hubner, Richard

Braiteh, Fadi S.

Pipas, J. Marc

Belanger, Bruce

de Jong, Floris A.

Mody, Purvi D.

Von Hoff, Daniel D.

Siveke, Jens T.

机构：

[1] Washington Univ, Sch Med St Louis, St Louis, MO USA

[2] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan

[3] Taipei Vet Gen Hosp, Taipei, Taiwan

[4] Szent Laszlo Teaching Hosp, Budapest, Hungary

[5] St John God Hosp, Subiaco, WA, Australia

[6] Seoul Natl Univ Hosp, Seoul, South Korea

[7] Royal Marsden Hosp, Sutton, Surrey, England

[8] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[10] Merrimack Pharmaceut Inc, Cambridge, MA USA

[11] Shire GmbH, Zug, Switzerland

[12] Translat Genom Res Inst TGen, Phoenix, AZ USA

[13] HonorHealth, Phoenix, AZ USA

[14] Univ Hosp, West German Canc Ctr, Essen, Germany

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.e15795

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e15795

引用

页数：6